A five-phase study (discovery phase [discovery set 1, the discovery set 2], validation phase 1, validation phase 2, supplemental phase, and cohort phase) design. (A) The workflow of the discovery …
(A) All the primary angle closure glaucoma (PACG) patients; (B) discovery set 1; (C) discovery set 2; (D) validation phase 1; (E) validation phase 2.
(A) Orthogonal projection to latent structure-discriminant analysis (OPLS-DA) score plot of the comparison between the PACG and NC groups in the discovery phase (discovery set 1 and discovery set …
(A) Heatmap of the area under the receiver operating characteristic curve assessing the discriminating accuracy of each of the 32 metabolites in differentiating PACG from normal control in the …
(A) A heatmap of correlation analysis between ocular clinical characteristics and 32 potential biomarkers in the discovery phase in PACG subjects. (B) The serum level of androstenedione between PACG …
(A) The serum level of androstenedione between PACG and normal group in validation phase 1 (unit for y-axis is peak areas). (B) The serum level of androstenedione between PACG and normal group in …
(A) Androstenedione to discriminate primary angle closure glaucoma (PACG) from normal in the discovery set in male subjects. (B) Androstenedione to discriminate PACG from normal in the discovery set …
(A) Comparison of mean serum levels of androstenedione between mild, moderate, and severe PACG in the discovery set 1 (unit for y-axis is peak areas). (B) Comparison mean serum levels of …
(A) Androstenedione to discriminates mild, moderate, and severe PACG in discovery set 1. (B) Androstenedione to discriminates mild, moderate, and severe PACG in discovery set 2. (C) Androstenedione …
(A) Sampling scheme and workflow to investigate the temporal changes in androstenedione levels. (B) Differential level of serum androstenedione between patients with PACG before and 3 months after …
(A) Calibration curves in the discovery set 1. (B) Calibration curves in the discovery set 2. (C) Calibration curves in the validation phase 1. (D) Calibration curves in the validation phase 2. The …
(A) Male+female; (B) female; (C) male. We categorized study participants into two groups based on their mean levels of androstenedione.
(A) Steroid hormone biosynthesis related to androstenedione. (B) Aromatase function deficits may be the potential mechanism leading to androstenedione accumulation in patients with PACG. (C) Binding …
Normal (n=268) | PACG (n=348) | t/χ2 | p | |
---|---|---|---|---|
Discovery phase | ||||
Discovery set 1 | ||||
Number (n) | 60 | 80 | ||
Age (years) | 58.75±8.63 | 61.00±8.67 | 1.52 | 0.13 |
Sex (male, %) | 24 (40.0) | 31 (38.8) | 0.02 | 0.88 |
BMI (kg/m2) | 24.04±5.27 | 23.36±2.44 | 0.99 | 0.33 |
Hypercholesterolemia (yes, %) | 6 (10) | 9 (11.3) | 0.06 | 0.81 |
Hypertension (yes, %) | 16 (26.7) | 18 (22.8) | 0.32 | 0.60 |
Diabetes (yes, %) | 1 (1.7) | 8 (10.1) | 3.96 | 0.10 |
Smoking (yes, %) | 5 (8.3) | 11 (13.9) | 0.99 | 0.42 |
Drinking (yes, %) | 7 (11.7) | 8 (10.1) | 0.1 | 0.76 |
Duration (months) | 10.45±12.43 | |||
IOP (mmHg) | 12.22±4.50 | 27.78±11.20 | 10.17 | <0.001 |
VCDR | 0.25±0.18 | 0.64±0.23 | 10.87 | <0.001 |
AL (mm) | 22.48±1.14 | |||
ACD (mm) | 1.86±0.55 | |||
CCT (µm) | 534.04±41.26 | |||
MS (dB) | 12.46±8.75 | |||
MD (dB) | 14.67±8.94 | |||
Discovery set 2 | ||||
Number (n) | 80 | 100 | ||
Age (years) | 62.54±6.74 | 63.14±9.04 | 0.49 | 0.62 |
Sex (male, %) | 35 (43.8) | 33 (33.0) | 2.19 | 0.14 |
BMI (kg/m2) | 23.68±2.81 | 23.32±3.15 | 1.36 | 0.18 |
Hypercholesterolemia (yes, %) | 12 (15) | 13 (13) | 0.15 | 0.70 |
Hypertension (yes, %) | 26 (32.5) | 33 (33.0) | 0.01 | 0.94 |
Diabetes (yes, %) | 7 (8.8) | 9 (9.0) | 0.003 | 0.95 |
Smoking (yes, %) | 11 (13.8) | 15 (15.0) | 0.06 | 0.81 |
Drinking (yes, %) | 19 (23.8) | 22 (22.0) | 0.08 | 0.78 |
Duration (months) | 8.46±9.69 | |||
IOP (mmHg) | 11.45±5.21 | 25.80±12.55 | 8.329 | <0.001 |
VCDR | 0.27±0.14 | 0.61±0.22 | 10.48 | <0.001 |
AL (mm) | 22.43±0.75 | |||
ACD (mm) | 2.05±0.77 | |||
CCT (µm) | 547.43±43.04 | |||
MS (dB) | 12.34±8.55 | |||
MD (dB) | 14.50±8.95 | |||
Validation phase 1 | ||||
Number (n) | 50 | 70 | ||
Age (years) | 57.47±8.17 | 60.34±10.11 | 1.66 | 0.10 |
Sex (male, %) | 18 (36.0) | 24 (34.3) | 0.04 | 0.85 |
BMI (kg/m2) | 23.08±1.99 | 24.45±3.72 | 1.31 | 0.19 |
Hypercholesterolemia (yes, %) | 4 (8) | 8 (11.4) | 0.38 | 0.54 |
Hypertension (yes, %) | 17 (34.0) | 21 (30.0) | 0.22 | 0.64 |
Diabetes (yes, %) | 5 (10.0) | 7 (10.0) | 0.0 | 1.0 |
Smoking (yes, %) | 6 (12.0) | 10 (14.3) | 0.13 | 0.72 |
Drinking (yes, %) | 10 (20.0) | 15 (21.4) | 0.04 | 0.85 |
Duration (months) | 11.09±13.82 | |||
IOP (mmHg) | 12.90±4.11 | 28.46±9.80 | 11.55 | <0.001 |
VCDR | 0.24±0.17 | 0.60±0.21 | 10.87 | <0.001 |
AL (mm) | 22.44±0.83 | |||
ACD (mm) | 1.86±0.37 | |||
CCT (µm) | 539.09±82.70 | |||
MS (dB) | 13.78±8.58 | |||
MD (dB) | 13.96±9.29 | |||
Validation phase 2 | ||||
Number (n) | 78 | 98 | ||
Age (years) | 56.55±11.53 | 60.26±15.41 | 1.77 | 0.08 |
Sex (male, %) | 29 (37.2) | 48 (49.0) | 2.46 | 0.12 |
BMI (kg/m2) | 24.54±5.42 | 25.90±7.51 | 1.26 | 0.21 |
Hypercholesterolemia (yes, %) | 11 (14.1) | 13 (13.3) | 0.03 | 0.87 |
Hypertension (yes, %) | 19 (24.4) | 31 (31.6) | 0.26 | 0.61 |
Diabetes (yes, %) | 6 (7.7) | 17 (17.3) | 3.6 | 0.06 |
Smoking (yes, %) | 9 (11.5) | 22 (22.4) | 3.6 | 0.06 |
Drinking (yes, %) | 12 (15.4) | 19 (19.4) | 0.48 | 0.49 |
Duration (months) | 11.40±13.8 | |||
IOP (mmHg) | 13.40±5.43 | 29.20±11.20 | 10.07 | <0.001 |
VCDR | 0.30±0.19 | 0.68±0.23 | 10.41 | <0.001 |
AL (mm) | 23.20±1.72 | |||
ACD (mm) | 2.15±0.67 | |||
CCT (µm) | 546.71±50.35 | |||
MS (dB) | 11.07±8.54 | |||
MD (dB) | 16.49±8.64 |
BMI = body mass index; IOP = intraocular pressure, VCDR = vertical cup-to-disc ratio, AL = axial length, CCT = central corneal thickness, ACD = anterior chamber depth, MD: visual field mean deviation, MS: visual field mean sensitivity, PACG = primary angle closure glaucoma.
Univariate | Multivariate* | |||
---|---|---|---|---|
p | HR (95% CI) | p | HR (95% CI) | |
Age | 0.008 | 0.97 (0.95–0.99) | 0.22 | 0.98 (0.95–1.01) |
Sex | 0.87 | 0.95 (0.53–1.72) | 0.73 | 1.15 (0.53–2.52) |
IOP | 0.59 | 1.007 (0.98–1.04) | 0.75 | 0.99 (0.96–1.03) |
VCDR | 0.17 | 0.40 (0.11–1.46) | 0.16 | 0.37 (0.092–1.46) |
CCT | 0.77 | 1.001 (0.10–1.007) | 0.90 | 1.000 (0.99–1.007) |
ACD | 0.03 | 1.63 (1.05–2.52) | 0.91 | 1.041 (0.51–2.13) |
AL | 0.005 | 1.24 (1.07–1.44) | 0.35 | 1.12 (0.89–1.41) |
MD | 0.13 | 1.04 (0.99–1.08) | 0.075 | 1.047 (0.10–1.10) |
Androstenedione | <0.001 | 3.73 (1.84–7.57) | 0.017 | 2.71 (1.20–6.10) |
Adjusted for BMI, diabetes (yes = 1, no = 0), hypertension (yes = 1, no = 0), hypercholesterolemia (yes = 1, no = 0), smoking (yes = 1, no = 0), and drinking (yes = 1, no = 0). Bold values indicate positive results.
IOP =intraocular pressure, VCDR =vertical cup-to-disc ratio, AL =axial length, CCT =central corneal thickness, ACD =anterior chamber depth, MD =mean deviation, PACG =primary angle closure glaucoma.
List of statistical approach and packages.
The clinical and demographic characteristics of primary angle closure glaucoma (PACG) and cataract subjects in the supplemental phase.
The clinical and demographic characteristics of same primary angle closure glaucoma (PACG) patients between pre-treatment and post-treatment.
The differential metabolites associated with primary angle closure glaucoma (PACG) and their fold changes in discovery set 1.
The differential metabolites associated with primary angle closure glaucoma (PACG) and their fold changes in discovery set 2.
The detecting parameters of 32 differential metabolites.
The relationship between androstenedione and risk of primary angle closure glaucoma (PACG).
The results of receiver operating characteristic (ROC) curve.
Comparison of characteristics of no progression and progression group in primary angle closure glaucoma (PACG) patients.
Comparison of areas under the receiver operating characteristic curve (AUCs) value among docosahexaenoic acid (DHA), free fatty acid (FFA) (22:6), free fatty acid (FFA) (18:4), and androstenedione.